Risk factors for hepatic steatosis in adults with cystic fibrosis: Similarities to non-alcoholic fatty liver disease

Table 2 Comparison of biomarkers between patients found to have hepatic steatosis and those without steatosis on imaging

Biomarker	Data by hepatic steatosis		P value
	Hepatic steatosis (n = 17, 15%)	No hepatic steatosis (n = 97, 85%)
AST	23 (20-29)	21 (16-26)	0.284
ALT	27 (19-36)	19 (13-32)	0.048a
ALP	103 (75-120)	99 (73-150)	0.793
Platelets	279 (244-311)	270 (207-342)	0.764
Total bilirubin	0.3 (0.3-0.4)	0.4 (0.2-0.5)	0.022a
INR	1 (1-1.1)	1 (1-1.1)	0.350
Albumin	3.7 (3.5-4.2)	4.2 (3.8-4.4)	0.034a
LDL	78.5 (44-89)	63.5 (45-81)	0.424
HDL	36.5 (31-42)	45 (36-56.5)	0.091
Triglycerides	78.5 (65-96)	80.5 (62-114.5)	0.756
Total cholesterol	124.5 (93-152)	133 (103-162.5)	0.819
HbA1c	6.5 (5.8-7.1)	6.1 (5.5-6.7)	0.097

^aP < 0.05. AST: Aspartate aminotransferase; ALP: Alkaline phosphatase; ALT: Alanine aminotransferase; INR: International normalized ratio; LDL: Low-density lipoprotein; HDL: High-density lipoprotein; HbA_1c: Hemoglobin A_1c.